Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$0.22
<$0.01(2.52%)
At close: 4:00 PM EDT
$0.22
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.13 - $3.11
Previous CloseN/A
Volume131.13K
Average Volume (3M)5.93M
Market Cap
$4.41M
Enterprise Value$19.70M
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$12.14M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 18, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding33,609,394
10 Day Avg. Volume2,752,284
30 Day Avg. Volume5,928,851
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap4.47
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$23.86M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong year-over-year growth shows increasing demand for Vivos’ diagnostics, treatment, and related services. The expansion is supported by higher service revenue and broader patient activity, giving the company a potentially larger recurring customer base over the next several quarters.
Margin And Capacity ExpansionImproving gross margins indicate that incremental revenue may generate better contribution economics, while expanded Henderson capacity provides room to serve more patients. Together, these developments can support operating leverage if utilization rises and the new capacity converts into sustained volume.
Technology And Strategic IPBroader patent coverage can make the company’s oral-appliance technology harder to design around and may reinforce differentiation in non-CPAP sleep treatment. The protected platform, combined with existing FDA clearances cited in the article, supports longer-term commercialization and provider adoption.
Bears Say
Persistent Operating LossesWidening losses despite revenue growth show that the current expense base remains far above the company’s gross-profit contribution. Until new services scale enough to improve operating leverage, continued losses may consume resources and make the path to sustainable profitability dependent on aggressive execution.
Cash Burn And LiquidityHeavy operating cash burn and very limited cash leave little financial flexibility to fund growth initiatives or absorb delays. The company states that existing cash will not support operations and strategic objectives for the next 12 months, making additional financing an important condition for continuity.
Product Revenue Mix PressureFalling appliance revenue while unit volume rises indicates unfavorable mix and lower revenue per treatment component. This pressure can limit the benefit of the company’s core product growth, weaken overall monetization, and require service expansion or pricing improvement to restore durable revenue quality.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.13 and its highest was $3.10 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $4.41M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 30 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.1.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 33,609,394 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational progress: solid revenue growth (Q2 +35%, YTD +51%), improving gross margins, tangible contributions from the Sleep Center of Nevada (sleep testing, treatment), and multiple identified recurring-revenue initiatives (remote monitoring, DME CPAP, EEG/insomnia, pediatric program). However, material financial challenges dominate the risk profile — rising operating losses and cost of sales, heavy cash burn ($9.2M YTD), just $1.8M of cash on hand, substantial doubt about the company’s ability to continue as a going concern, and non-compliance with NASDAQ equity requirements that could trigger delisting. Management’s path to cash-flow positivity by late 2026/early 2027 is plausible but highly execution-dependent and contingent on securing additional financing. Given the severity of near-term liquidity and regulatory (NASDAQ) risks despite operational momentum, the negatives weigh heavily.View all VVOS earnings summariesTechnical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
5.26% Insiders
0.93% Mutual Funds
0.10% Other Institutional Investors
93.53% Public Companies and
Individual Investors